17 results on '"Rauch, A."'
Search Results
2. Environmental Impact and Cost Assessment for Reusing Waste during End-of-Life Activities on Building Projects.
- Author
-
Saeed, Fam, Mostafa, Kareem, Rauch, Christopher, and Hegazy, Tarek
- Subjects
WASTE recycling ,ENVIRONMENTAL impact analysis ,CONSTRUCTION & demolition debris ,CONSTRUCTION projects ,DECISION support systems - Abstract
The construction industry contributes significantly to global environmental loads with massive amounts of construction and demolition waste (CDW) ending up in landfills. To address the need for efficient CDW management, this research proposes a new decision support framework for managing construction waste generated during end-of-life activities for building projects. The framework monetizes potential environmental savings from different recovery options (e.g., reuse, recycle, and so on) and uses multiobjective optimization to determine the optimal quantity of material to undergo each material recovery scenario. The framework uses parametric weights to consider stakeholders' preferences and their appreciation of environmental benefits compared with costs. A case study of a renovation project in Waterloo, Ontario, Canada, is used to demonstrate how the proposed framework can divert concrete and glass waste from the landfill. For this particular project, savings of 200 GJ of embodied energy, 22 m3 of water, and over 12 t of greenhouse gases can be realized from optimal recovery planning using the proposed framework. This study concludes that decision support systems should be used well in advance of end-of-life activities to evaluate trade-offs for recovery planning activities effectively. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. The Arts 3D VLE Metaverse as a Network of Imagination
- Author
-
Rauch, Ulrich, Cohodas, Marvin, and Wang, Tim
- Abstract
Ulrich Rauch, Marvin Cohodas, and Tim Wang describe the Arts Metaverse, a Croquet-based virtual learning environment under development at the University of British Columbia. The Arts Metaverse allows three-dimensional virtual reconstruction of important artifacts and sites of classical, ancient, and indigenous American art, thereby allowing students access to places and works they would not otherwise be able to experience. The Arts Metaverse has been developed on the principle that engaging students in the construction of a virtual teaching and learning environment can facilitate collaboration between teachers and students and create a participative learning experience. In this spirit, the Arts Metaverse Project aims to make students and academics joint researchers creating and sharing knowledge beyond the walls of the university. While projects developed for the Arts Metaverse thus far have focused on art and architecture, the technology and process are entirely appropriate for a wide range of inquiries in the humanities and social sciences.
- Published
- 2009
4. Online Learning and Intellectual Liberty: A Mixed-Mode Experiment in the Humanities
- Author
-
Breton, Rob, Doak, Steve, Foster, Wendy, Lundstrom, Desiree, McMaster, Lindsey, Miller, Jeff, Rauch, Ulrich, Reid, Morgan, Scott, Warran, Wang, Tim, and Wisenthal, Jonathan
- Abstract
A mixed-mode university course, combining online learning and face-to-face meetings, can encourage students to formulate and express their own ideas more than would be the case in traditional classrooms. This article describes an experimental project at the University of British Columbia and explores connections between online learning and aspects of liberal humanism.
- Published
- 2005
5. Suicidality in Rural Communities: A Scoping Review of Research in Canada.
- Author
-
Rauch, Kyrra, Ryan, Kim, Ramsey, Doug, Epp, Donna, Lee, Stacey, Herron, Rachel, Mullins, Sharran, Thomson, Andrea E., and Waddell-Henowitch, Candice
- Subjects
SUICIDE prevention ,SUICIDE risk factors ,SUICIDE ,CINAHL database ,PSYCHOLOGY information storage & retrieval systems ,MEDICAL information storage & retrieval systems ,SYSTEMATIC reviews ,SUICIDAL ideation ,RISK assessment ,DESCRIPTIVE statistics ,RESEARCH funding ,LITERATURE reviews ,MEDLINE ,RURAL population ,PSYCHOSOCIAL factors - Abstract
Copyright of Canadian Journal of Community Mental Health is the property of Canadian Periodical for Community Studies Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
6. Rural Perspectives on Suicide Prevention in Canada.
- Author
-
Thomson, Andrea E., Waddell-Henowitch, Candice, Herron, Rachel, Epp, Donna, Rauch, Kyrra, Ryan, Kimberley D., and Mullins, Sharran
- Subjects
SUICIDE risk factors ,AFFINITY groups ,SOCIAL support ,FOCUS groups ,HEALTH services accessibility ,SUICIDE prevention ,RURAL conditions ,SOCIAL workers ,PEER counseling ,RISK assessment ,QUALITATIVE research ,PATIENTS' attitudes ,DESCRIPTIVE statistics ,RURAL population - Abstract
Copyright of Canadian Journal of Community Mental Health is the property of Canadian Periodical for Community Studies Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
7. Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta.
- Author
-
Boitor, Madalina, Gélinas, Céline, Rauch, Frank, Jacob, Eufemia, LeMay, Sylvie, Carrier, Jaimie Isabel, Bilodeau, Claudette, and Tsimicalis, Argerie
- Subjects
PAIN measurement ,OSTEOGENESIS imperfecta ,TEENAGERS ,CRONBACH'S alpha ,TEST reliability - Abstract
Copyright of Canadian Journal of Pain is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
8. Vitamin D status and functional health outcomes in children aged 2-8 y: a 6-mo vitamin D randomized controlled trial.
- Author
-
Brett, Neil R, Parks, Colleen A, Lavery, Paula, Agellon, Sherry, Vanstone, Catherine A, Kaufmann, Martin, Jones, Glenville, Maguire, Jonathon L, Rauch, Frank, and Weiler, Hope A
- Subjects
ANTHROPOMETRY ,BIOMARKERS ,BODY composition ,COMPUTED tomography ,INGESTION ,LIFE skills ,LIQUID chromatography ,MASS spectrometry ,MUSCLE strength ,MUSCULOSKELETAL system physiology ,STATISTICAL sampling ,SURVEYS ,TIBIA ,VITAMIN D ,RANDOMIZED controlled trials ,PHYSICAL activity ,NUTRITIONAL status ,PHOTON absorptiometry - Abstract
Background: Most Canadian children do not meet the recommended dietary intake for vitamin D. Objectives: The aims were to test how much vitamin D from food is needed to maintain a healthy serum 25-hydroxyvitamin D
3 [25(OH)D3 ] status from fall to spring in young children and to examine musculoskeletal outcomes. Design: Healthy children aged 2-8 y (n = 51) living in Montreal, Canada, were randomly assigned to 1 of 2 dietary vitamin D groups (control or intervention to reach 400 lU/d by using vitamin D- fortified foods) for 6 mo, starting October 2014. At baseline and at 3 and 6 mo, anthropometric characteristics, vitamin D metabolites (liquid chromatography-tandem mass spectrometry), and bone biomarkers (IDS-iSYS, Immunodiagnositc Systems; Liaison; Diasorin) were measured and physical activity and food intakes surveyed. At baseline and at 6 mo, bone outcomes and body composition (dual-energy X-ray absorptiometry) were measured. Cross-sectional images of distal tibia geometry and muscle density were conducted with the use of peripheral quantitative computed tomography scans at 6 mo. Results: At baseline, participants were aged 5.2 ± 1.9 (mean ± SD) y and had a body mass index z score of 0.65 ± 0.12; 53% of participants were boys. There were no differences between groups in baseline serum 25(OH)D3 (66.4 ± 13.6 nmol/L) or vitamin D intake (225 ± 74 lU/d). Median (IQR) compliance was 96% (89-99%) for yogurt and 84% (71-97%) for cheese. At 3 mo, serum 25(OH)D3 was higher in the intervention group (P < 0.05) but was not different between groups by 6 mo. Although lean mass accretion was higher in the intervention group (P < 0.05), no differences in muscle density or bone outcomes were observed. Conclusions: The consumption of 400 IU vitamin D/d from fall to spring did not maintain serum 25(OH)D3 concentration or improve bone outcomes. Further work with lean mass accretion as the primary outcome is needed to confirm if vitamin D enhances lean accretion in healthy young children. This trial was registered at www.clinicaltrials.gov as NCT02387892. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. Osteogenesis Imperfecta Type VI in Individuals from Northern Canada.
- Author
-
Ward, Leanne, Bardai, Ghalib, Moffatt, Pierre, Al-Jallad, Hadil, Trejo, Pamela, Glorieux, Francis, Rauch, Frank, and Glorieux, Francis H
- Subjects
OSTEOGENESIS imperfecta ,PUBLIC health ,GENETIC mutation ,GENETIC code ,EPITHELIUM - Abstract
Osteogenesis imperfecta (OI) type VI is a recessively inherited form of OI that is caused by mutations in SERPINF1, the gene coding for pigment-epithelium derived factor (PEDF). Here, we report on two apparently unrelated children with OI type VI who had the same unusual homozygous variant in intron 6 of SERPINF1 (c.787-10C>G). This variant created a novel splice site that led to the in-frame addition of three amino acids to PEDF (p.Lys262_Ile263insLeuSerGln). Western blotting showed that skin fibroblasts with this mutation produced PEDF but failed to secrete it. Both children were treated with intravenous bisphosphonates, but the treatment of Individual 1 was switched to subcutaneous injections of denosumab (dose 1 mg per kg body weight, repeated every 3 months). An iliac bone sample obtained after 5 denosumab injections (and 3 months after the last injection) showed no change in the increased osteoid parameters that are typical of OI type VI, but the number of osteoclasts in trabecular bone was markedly increased. This suggests that the effect of denosumab on osteoclast suppression is of shorter duration in children with OI type VI than what has previously been reported on adults with osteoporosis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Dietary vitamin D dose-response in healthy children 2 to 8 y of age: a 12-wk randomized controlled trial using fortified foods.
- Author
-
Brett, Neil R., Lavery, Paula, Agellon, Sherry, Vanstone, Catherine A., Maguire, Jonathon L., Rauch, Frank, and Weiler, Hope A.
- Subjects
ENRICHED foods ,ANALYSIS of variance ,ANTHROPOMETRY ,BODY composition ,CALCIUM ,CHEESE ,CHI-squared test ,CHILDREN'S health ,CHILD nutrition ,CLINICAL trials ,HUMAN skin color ,DAIRY products ,DOSE-response relationship in biochemistry ,FISHER exact test ,LONGITUDINAL method ,NUTRITIONAL assessment ,NUTRITION policy ,NUTRITIONAL requirements ,PARATHYROID hormone ,PROBABILITY theory ,QUESTIONNAIRES ,REGRESSION analysis ,RESEARCH funding ,STATISTICAL sampling ,SEASONS ,STATISTICS ,SUNSHINE ,VITAMIN D ,YOGURT ,STATISTICAL power analysis ,DATA analysis ,ENVIRONMENTAL exposure ,SOCIOECONOMIC factors ,STATISTICAL significance ,BODY mass index ,RANDOMIZED controlled trials ,BLIND experiment ,DATA analysis software ,DESCRIPTIVE statistics ,NUTRITIONAL status ,PHOTON absorptiometry ,CHILDREN - Abstract
Background: Vitamin D is fundamental for bone health. A high proportion of Canadian 2- to 8-y-olds do not meet the Estimated Average Requirement (EAR) of 400 IU/d. Objective: The objective was to determine whether vitamin D intakes consistent with the EAR or Recommended Dietary Allowance (RDA), through fortification of additional dairy products, would result in higher vitamin D status in young children. Design: Participants aged 2-8 y (n = 77; Montreal, Canada) were randomly assigned to 1 of 3 dietary vitamin D targets (control; EAR: 400 IU/d; or RDA: 600 IU/d) for 12 wk (January to April 2014). Anthropometric measurements, demographic characteristics, dietary intakes, fasting serum parathyroid hormone, 25-hydroxyvitamin D [25(OH)D], and ionized calcium were compared by using mixed-model ANOVA. Results: Participants' mean ± SD age was 5.1 ± 1.9 y; 54.5% were boys with body mass index z scores of 0.50 ± 0.85. Compliance was 85% overall. No differences were observed in baseline dietary vitamin D intakes or serum 25(OH)D. At 12 wk, the EAR and RDA groups had significantly higher vitamin D intakes [median (IQR): control, 227 (184-305) IU/d; EAR, 410 (363-516) IU/d; and RDA, 554 (493-653) IU/d; P < 0.05] and serum 25(OH)D concentrations (control: 55.8 ± 12.3 nmol/L; EAR: 64.1 ± 10.0 nmol/L; and RDA: 63.7 ± 12.4 nmol/L; P < 0.05) than the control group. Ninety-six percent of children in the EAR and RDA groups and 67% of the control group had 25(OH)D concentrations ≥50 nmol/L. Conclusion: Increasing the vitamin D intakes of young children through fortification of alternative dairy products results in significantly higher serum concentrations of 25(OH)D and a significantly greater proportion of children with serum 25(OH)D ≥50 nmol/L during periods of minimal ultraviolet B radiation exposure. This trial was registered at clinicaltrials.gov as NCT02097160 and had Health Canada Temporary Marketing Authorization Letters for both products (TM-13-0432 and TM-13-0433). [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
- Author
-
Nüßlein, Hubert G., Alten, Rieke, Galeazzi, Mauro, Lorenz, Hanns-Martin, Boumpas, Dimitrios, Nurmohamed, Michael T., Bensen, William G., Burmester, Gerd R., Peter, Hans-Hartmut, Rainer, Franz, Pavelka, Karel, Chartier, Melanie, Poncet, Coralie, Rauch, Christiane, and Le Bars, Manuela
- Subjects
ABATACEPT ,RHEUMATOID arthritis treatment ,DRUG efficacy ,DRUG tolerance ,ADVERSE health care events - Abstract
Background Discontinuation of rheumatoid arthritis (RA) treatment for lack or loss of initial response, tolerability issues, or development of antibodies against the therapeutic agent remains a challenge in clinical practice. Here we present a 6-month interim analysis of a 2-year prospective observational trial in Europe and Canada aiming to assess the real-world effectiveness, safety, and tolerability of intravenous abatacept for the treatment of moderateto- severe RA. Methods ACTION (AbataCepT In rOutiNe clinical practice) is a prospective, observational study assessing effectiveness, safety, and tolerability of abatacept in patients with RA enrolled in Europe and Canada between May 2008 and January 2011. The patient population was divided into two groups: biologic naïve (‘first-line’) patients and patients who had previously failed treatment with at least one biologic agent (‘second-line’). Retention rates were calculated using Kaplan–Meier curve estimates. Effectiveness was measured using European League Against Rheumatism (EULAR) response criteria, the 28-item Disease Activity Score, the Clinical Disease Activity Index (CDAI), and physical function, as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI). Serious adverse events (SAEs) were reported for all enrolled patients. Results Of 1138 consecutively enrolled patients, 1114 and 1079 patients were evaluable for retention and effectiveness, respectively. Overall, retention rates were 88.6% (95% confidence interval [CI]: 86.4, 90.4); 67.4% of patients achieved good/moderate EULAR response; 32.8% had a CDAI Low Disease Activity State (LDAS); and 44.7% a HAQ-DI response. Retention rates among first- and second-line patients were 93.0% (95% CI: 85.9, 96.6) and 88.1% (95% CI: 85.7, 90.0), respectively. The percentage of patients achieving CDAI LDAS was 40.0% (95% CI: 26.4, 53.6) for first- and 32.2% (95% CI: 28.4, 36.0) for second-line patients and the proportion achieving a HAQ-DI response was 60.3% (95% CI: 47.8, 72.9) versus 43.1% (95% CI: 39.0, 47.2), respectively. The incidence of SAEs was 4.7%. Conclusions Evidence from this 6-month interim analysis suggests that abatacept offers an effective and well-tolerated treatment option for patients with RA, including those who have previously failed anti-tumor necrosis factor treatment. In addition, higher retention rates and effectiveness outcomes were observed when abatacept treatment was initiated earlier in the course of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Vitamin D Status in Montréal Preschoolers Is Satisfactory Despite Low Vitamin D Intake.
- Author
-
Hayek, Jessy El, Pham, Thu Trang, Finch, Sarah, Hazell, Tom J., Jean-Philippe, Sonia, Vanstone, Catherine A., Agellon, Sherry, Rodd, Celia, Rauch, Frank, and Weiler, Hope A.
- Subjects
VITAMIN D ,PRESCHOOL children ,ANTHROPOMETRY ,HEALTH surveys ,STEROID hormones - Abstract
The 2007 to 2009 Canadian Health Measures Survey reported vitamin D status in a representative sample of Canadians (6-79 y); however, children <6 y were not assessed. Our objective was to measure vitamin D intake from food and supplements, sun exposure, and biological vitamin D status of children ages 2 through 5 y in Montréal (latitude 45°N). Preschoolers (in = 508) were recruited between June 2010 and 2011 in a random sample of licensed daycares in the regions of greater Montreal, Canada in a cross-sectional study. The total plasma 25-hydroxyvitamin D [25(OH)DI concentration was measured using a chemiluminescence assay (Liaison, Diasorin). Dietary intake was assessed during one 24-h period plus a 30-d FFQ. Socioeconomic, demographic, anthropometry, and sun exposure data were collected. Plasma 25(OH)D was ≥50 nmol/L in 88% of children, whereas 49.4% had concentrations ≥75 nmol/L during the 1-y study. Almost 95% of preschoolers had vitamin D intakes less than the Estimated Average Requirement (EAR), and 4.8% of preschoolers ≤3.9 y and 25.9% of preschoolers ≥4 y had calcium intakes less than the EAR. Plasma 25(OH)D was different across age, income, sun index, milk intake, and dietary and supplemental vitamin D intake tertiles. Despite vitamin D intakes less than the EAR, the vitamin D status of Montréal preschoolers attending daycare is mostly satisfactory even in winter, suggesting that the EAR value is too high in the context of typical exogenous intakes of vitamin D in North America. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
- Author
-
Requena, Maria-Bernarda, Protopopescu, Camelia, Stewart, Ashleigh C., van Santen, Daniela K., Klein, Marina B., Jarrin, Inmaculada, Berenguer, Juan, Wittkop, Linda, Salmon, Dominique, Rauch, Andri, Prins, Maria, van der Valk, Marc, Sacks-Davis, Rachel, Hellard, Margaret E, Carrieri, Patrizia, and Lacombe, Karine
- Subjects
- *
MORTALITY , *SEX distribution , *HIV infections , *TREATMENT effectiveness , *AGE distribution , *DESCRIPTIVE statistics , *ANTIVIRAL agents , *INTERNATIONAL relations , *PRE-tests & post-tests , *MEN who have sex with men , *HEPATITIS C , *COMPARATIVE studies , *CONFIDENCE intervals , *MIXED infections , *PROPORTIONAL hazards models , *COMORBIDITY , *EVALUATION - Abstract
Among people living with HIV and hepatitis C virus (HCV), people who inject drugs (PWID) have historically experienced higher mortality rates. Direct-acting antivirals (DAA), which have led to a 90 % HCV cure rate independently of HIV co-infection, have improved mortality rates. However, DAA era mortality trends among PWID with HIV/HCV remain unknown. Using data from the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC), we compared pre/post-DAA availability mortality changes in three groups: PWID, men who have sex with men (MSM), and all other participants. We included InCHEHC participants with HIV/HCV followed between 2010 and 2019 in Canada, France, the Netherlands, Spain, and Switzerland. All-cause mortality hazard was compared in the three groups, using Cox proportional hazards regression models adjusted for sex, age, advanced fibrosis/cirrhosis, and pre/post DAA availability. Of the 11,029 participants, 76 % were men, 46 % were PWID, baseline median age was 46 years (interquartile range [IQR] = 40;51), and median CD4 T-cell count was 490 cells/mm3 (IQR = 327;689). Over the study period (median follow-up = 7.2 years (IQR = 3.7;10.0)), 6143 (56 %) participants received HCV treatment, 4880 (44 %) were cured, and 1322 participants died (mortality rate = 1.81/100 person-years (PY) [95 % confidence interval (CI)=1.72–1.91]). Overall, PWID had higher mortality rates than MSM (2.5/100 PY [95 % CI = 2.3–2.6] vs. 0.8/100 PY [95 % CI = 0.7–0.9], respectively). Unlike women with other transmission modes, those who injected drugs had a higher mortality hazard than men who did not inject drugs and men who were not MSM (adjusted Hazard-Ratio (aHR) [95 % CI] = 1.3[1.0–1.6]). Post-DAA availability, mortality decreased among MSM in the Netherlands, Spain, and Switzerland and increased among PWID in Canada (aHR [95 % CI] = 1.73 [1.15–2.61]). Post-DAA availability, all-cause mortality did not decrease in PWID. Determinants of cause-specific deaths (drug-related, HIV-related, or HCV-related) need to be identified to explain persistently high mortality among PWID in the DAA era. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Psychosocial Adjustment in School-age Girls With a Family History of Breast Cancer.
- Author
-
Bradbury, Angela R., Patrick-Miller, Linda, Schwartz, Lisa, Egleston, Brian, Burke Sands, Colleen, Chung, Wendy K., Glendon, Gord, McDonald, Jasmine A., Moore, Cynthia, Rauch, Paula, Tuchman, Lisa, Andrulis, Irene L., Buys, Saundra S., Frost, Caren J., Keegan, Theresa H. M., Knight, Julia A., Terry, Mary Beth, John, Esther M., and Daly, Mary B.
- Subjects
- *
BREAST tumors , *ADAPTABILITY (Personality) in children , *ANXIETY , *CONFIDENCE intervals , *MENTAL depression , *HEALTH behavior , *MULTIVARIATE analysis , *GENETIC mutation , *PUBERTY , *RESEARCH funding , *SCALE analysis (Psychology) , *PSYCHOLOGICAL stress , *GENETIC testing , *MULTIPLE regression analysis , *BRCA genes , *FAMILY history (Medicine) , *ODDS ratio , *CHILDREN , *GENETICS , *CANCER & psychology - Abstract
OBJECTIVE: Understanding how young girls respond to growing up with breast cancer family histories is critical given expansion of genetic testing and breast cancer messaging. We examined the impact of breast cancer family history on psychosocial adjustment and health behaviors among >800 girls in the multicenter LEGACY Girls Study. METHODS: Girls aged 6 to 13 years with a family history of breast cancer or familial BRCA1/2 mutation (BCFH+), peers without a family history (BCFH-), and their biological mothers completed assessments of psychosocial adjustment (maternal report for 6- to 13-year-olds, self-report for 10- to 13-year-olds), breast cancer-specific distress, perceived risk of breast cancer, and health behaviors (10- to 13-year-olds). RESULTS: BCFH+ girls had better general psychosocial adjustment than BCFH- peers by maternal report. Psychosocial adjustment and health behaviors did not differ significantly by self-report among 10- to 13-year-old girls. BCFH+ girls reported higher breast cancer-specific distress (P = .001) and were more likely to report themselves at increased breast cancer risk than BCFH- peers (38.4% vs 13.7%, P < .001), although many girls were unsure of their risk. In multivariable analyses, higher daughter anxiety was associated with higher maternal anxiety and poorer family communication. Higher daughter breast cancer-specific distress was associated with higher maternal breast cancer-specific distress. CONCLUSIONS: Although growing up in a family at risk for breast cancer does not negatively affect general psychosocial adjustment among preadolescent girls, those from breast cancer risk families experience greater breast cancer-specific distress. Interventions to address daughter and mother breast cancer concerns and responses to genetic or familial risk might improve psychosocial outcomes of teen daughters. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Family-Centered Rounds on Pediatric Wards: A PRIS Network Survey of US and Canadian Hospitalists.
- Author
-
Vineeta S. Mittal, Sigrest, Ted, Ottolini, Mary C., Rauch, Daniel, Hua Lin, Kit, Brian, Landrigan, Christopher P., and Flores, Glenn
- Subjects
- *
HOSPITALISTS , *FAMILY nursing , *CHILDREN'S hospitals , *HOSPITAL rounds , *SOCIODEMOGRAPHIC factors , *SURVEYS , *INPATIENT care - Abstract
OBJECTIVE: The goal was to examine pediatric hospitalist rounding practices and characteristics associated with programs conducting family-centered rounds (FCRs). METHODS: The Pediatric Hospitalist Triennial Survey, sent to a subset of pediatric hospitalists on the Pediatric Research in Inpatient Settings list serve from the United States and Canada, consisted of 63 questions on sociodemographic characteristics, training, practice characteristics, and rounding practices. RESULTS: Among 265 respondents (response rate: 70%), 78% practiced in academic hospitals and 22% in nonacademic hospitals. The prevalence's of specific rounding categories were as follows: FCRs, 44%; sit-down, 24%; hallway, 21%; others, 11%. FCRs occurred significantly more often in academic (48%) than nonacademic (31%) hospitals (P = .04). FCRs can include pediatric residents, bedside nurses, charge nurses, case managers, pharmacists, and social workers. Academic settings and higher average daily patient censuses, but not FCRs, were significantly associated with prolonged rounding duration. The most commonly perceived FCR benefits included increased family involvement and understanding, trainee role modeling, and effective team communication. Physical constraints, trainees' apprehensions, and time were the main perceived FCR barriers. Greater perceived benefit/barrier ratios, FCR benefits, and family involvement in care were associated with a greater likelihood of conducting FCRs, whereas a greater number of perceived FCR barriers was associated with not conducting FCRs. CONCLUSIONS: FCRs were the most-common rounding category among respondents. FCRs were not associated with a self-reported increase in rounding duration. Successful FCR implementation may require educating staff members and trainees about FCR benefits and addressing FCR barriers. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3.
- Author
-
Labuda, M., Morissette, J., Ward, L.M., Rauch, F., Lalic, L., Roughley, P.J., and Glorieux, F.H.
- Subjects
- *
OSTEOGENESIS imperfecta , *COLLAGEN , *GENETIC mutation - Abstract
We have identified a novel form of autosomal recessive osteogenesis imperfecta (OI) in a small First Nations community from northern Quebec. Mutation screening of the COL1A1/COL1A2 genes revealed no detectable mutations, and type I collagen protein analyses were also normal. By linkage analysis, we mapped this unique autosomal recessive variant of osteogenesis imperfecta to chromosome 3p22-24.1. Based on the assumption of a founder effect, genome-wide screening was performed on a DNA sample pooled from seven affected individuals. Familial as well as historical recombinations identified within an extended haplotype of 19 markers localized the disease between markers D3S2324 and D3S1561, separated by <5 cM. Based on chromosomal localization to 3p22-24.1, the transforming growth factor-β receptor 2 gene and the parathyroid hormone/parathyroid hormone-related peptide receptor were tested, but were excluded as being associated with the phenotype. This study excludes type I collagen mutations in the pathogenesis of the disease and assigns this form of OI to a locus other than the ones containing the type I collagen genes. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
17. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
- Author
-
Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, and Dore GJ
- Subjects
- Adult, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Australia, Canada, Carbamates therapeutic use, Drug Combinations, Female, Germany, Hepatitis C physiopathology, Heterocyclic Compounds, 4 or More Rings therapeutic use, Humans, Male, Middle Aged, Netherlands, New Zealand, Sofosbuvir therapeutic use, Switzerland, Treatment Outcome, United Kingdom, Carbamates pharmacology, Hepatitis C drug therapy, Heterocyclic Compounds, 4 or More Rings pharmacology, Sofosbuvir pharmacology, Time Factors
- Abstract
Background & Aims: Shortened duration therapy for acute and recent HCV infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens; however, large randomised studies are lacking., Methods: REACT was an NIH-funded multicentre international, open-label, randomised, phase IV non-inferiority trial examining the efficacy of short course (6-week) vs. standard course (12-week) therapy with sofosbuvir-velpatasvir for recent HCV infection (estimated duration of infection ≤12 months). Randomisation occurred at week 6. The primary endpoint was sustained virological response 12 weeks after treatment end (SVR12) in the intention-to treat (ITT) population. A total of 250 participants were due to be enrolled, but on advice of the data safety and monitoring board the study was halted early., Results: The primary analysis population consisted of 188 randomised participants at termination of study enrolment; short arm (n = 93), standard arm (n = 95). Ninety-seven percent were male and 69% HIV positive. ITT SVR12 was 76/93, 81.7% (95% CI 72.4-89.0) in the short arm and 86/95, 90.5% (95% CI 82.7-95.6) in the standard arm. The difference between the arms was -8.8 (95% CI -18.6 to 1.0). In modified ITT analysis, wherein non-virological reasons for failure were excluded (death, reinfection, loss to follow-up), SVR12 was 76/85, 89.4% (95% CI 80.8-95.0) in the short arm and 86/88, 97.7% in the standard arm (95% CI 92.0-99.7; difference -8.3%, p = 0.025)., Conclusions: In this randomised study in recent HCV infection, a 6-week course of sofosbuvir-velpatasvir did not meet the criteria for non-inferiority to standard 12-week therapy., Lay Summary: In this randomised trial, 188 people with recently acquired hepatitis C infection were randomly assigned to treatment using either a short 6-week course (93 people) or standard 12-week course (95 people) of the hepatitis C treatment sofosbuvir/velpatasvir. There were 9 cases of relapse after treatment with the short course and 2 following the standard course. A shortened course of 6-week therapy for hepatitis C infection appeared to be less effective than a standard 12-week course in people with recently acquired hepatitis C infection. CLINICALTRIALS., Gov Identifier: NCT02625909., Competing Interests: Conflict of interest GVM: grants from Gilead Sciences and AbbVie Inc, outside the submitted work; SB: grants from Gilead Sciences, outside the submitted work; personal fees for Advisory Boards and lectures/presentations from Gilead Sciences, outside the submitted work; MvDW: grants and personal fees from AbbVie, grants and personal fees from Gilead, grants and personal fees from Johnson & Johnson, grants and personal fees from MSD, grants and personal fees from ViiV, outside the submitted work; JR: personal fees from Gilead Sciences, Janssen, Merck, Theratechnologies and ViiV, outside the submitted work; JF: grants and personal fees from Gilead Sciences, grants and personal fees from AbbVie, personal fees from GSK, personal fees from Roche, grants from Janssen, grants from Eiger, grants and personal fees from Enanta, personal fees from Arubutus, outside the submitted work; AR: Advisory boards: MSD, Gilead Sciences, Travel grants: Gilead Sciences, Pfizer, AbbVie; Research support: Investigator initiated trial grant from Gilead Sciences. All remuneration went to his home institution and not to Dr. Rauch personally; CT: Gilead Advisory board (Remdesivir) 2020; MSD Advisory board (HCV) 2018; educational grants from Gilead and AbbVie (Annual Preceptorship on HCV in PWID), outside the submitted work; JB: grants from NIH, during the conduct of the study; personal fees from AbbVie, grants and personal fees from Gilead, outside the submitted work; AK: grants from PCORI, grants from NIH/NIAID, grants from NIH/NIA, grants from UpToDate, Inc., personal fees from Biomarin, Inc., personal fees for lectures/presentations: CME companies, Clinical Care Options companies, Mentor Planning and Practice Point, personal fees from DKBMed for communications, personal fees for academic work from Geisinger Health Systems and St. Luke’s/Roosevelt, personal fees from Ken Krayesek Law Offices, personal fees from Duke University, outside the submitted work; MH: grants from Gilead Sciences, grants from AbbVie, outside the submitted work; EG: personal fees from Gilead Scientific Advisory Board, personal fees from AbbVie Scientific Advisory Board, personal fees from Janssen Scientific Advisory Board, outside the submitted work; MN: grants, personal fees and non-financial support from AbbVie, grants, personal fees and non-financial support from MSD, grants, personal fees and non-financial support from BMS, grants, personal fees and non-financial support from Gilead Sciences, payment or honoraria: Gilead, AbbVie, BMS and MSD, travel support: Gilead, AbbVie, BMS and MSD, personal fees from MBS DMSB or equivalent, outside the submitted work; PI: grants and personal fees from Gilead Sciences, personal fees from AbbVie, personal fees from ViiV, outside the submitted work; JG: grants and personal fees from AbbVie, grants and personal fees from Gilead Sciences, grants and personal fees from Merck, grants and personal fees from Cepheid, grants from Hologic, grants from Indivior, payment or honoraria: AbbVie, Gilead Sciences and Cepheid, travel support: AbbVie, Gilead Sciences and Cepheid, receipt of testing equipment and cartridges from Cepheid, receipt of testing reagents from Hologic, outside the submitted work; KP: grants from Gilead sciences Australia and ViiV Healthcare Australia, outside the submitted work; GD: grants, personal fees and non-financial support from Gilead Sciences, AbbVie and Merck, grants from Bristol-Myers Squibb, outside the submitted work; DS, MM, TA and PM: nothing to disclose. Please refer to the accompanying ICMJE disclosure forms for further details., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.